Aviragen Therapeutics (AVIR) Tops Q2 EPS by 13c

Aviragen Therapeutics (NASDAQ: AVIR) reported Q2 EPS of ($0.34), $0.13 better than the analyst estimate of ($0.47). Revenue for the quarter came in at $0 versus the consensus estimate of $0 .

For earnings history and earnings-related data on Aviragen Therapeutics (AVIR) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Anterix Inc. (ATEX) Tops Q4 EPS by 152c
• Independent Bank receives regulatory approval for HCB Financial acquisition